Economic burden of acute myeloid leukemia: A literature review

Cancer Treatment Reviews

Volumn 30, Issue 3, 2004, Pages 237-247

  Redaelli, Alberto ^a   Botteman, Marc F ^b   Stephens, Jennifer M ^b   Brandt, Suzanne ^b   Pashos, Chris L ^c  

^a Pharmacia Corporation   (Italy)

^b HERQuLES   (United States)

^c HERQuLES   (United States)

Author keywords

Acute myeloid leukemia; Bone marrow transplantation; Chemotherapy; Colony stimulating factors; Copst of illness; Cost effectiveness; Economic burden; Peripheral blood stem cell transplantation

Indexed keywords

ANTIINFECTIVE AGENT; COLONY STIMULATING FACTOR; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; PLACEBO;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; BLEEDING; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SURVIVAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; ECONOMIC ASPECT; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HERPES ZOSTER; HOSPITAL ADMISSION; HUMAN; INFORMATION PROCESSING; LENGTH OF STAY; PNEUMONIA; PREVALENCE; PROGNOSIS; PROSPECTIVE PAYMENT; PUBLICATION; REVIEW; VEIN OCCLUSION;

EID: 1842690785     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2003.11.002     Document Type: Article

References (29)

1. Tennvall GR, Persson U, Nilsson B. The economic costs of acute myeioid leukemia in Sweden. Int J Technol Assess Health Care 1994;10(4):683-94.
2. Stalfelt AM. Quality of life of patients with acute myeloid leukaemia. Leuk Res 1994;18(4):257-67.
3. Greenberg DB, Kornblith AB, Herndon JE, et al. Quality of life for adult leukemia survivors treated on clinical trials of cancer and leukemia Group B during the period 1971-1988: predictors for later psychologic distress. Cancer 1997; 80(10):1936-44.
4. Uyl-de Groot CA, Gelderblom-den Hartog J, Huijgens PC, et al. Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the Netherlands. J Hematother Stem Cell Res 2001;10(1):187-92.
5. Stalfelt AM, Brodin H. Costs over time in conventional treatment of acute myeloid leukaemia. A study exploring changes in treatment strategies over two decades. J Intern Med 1994;236(4):401-9.
6. Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002;162(14):1597-603.
7. Stalfelt AM, Brodin H, Wadman B. Cost analysis of different phases of acute myeloid leukaemia. Leuk Res 1994;18(10): 783-90.
8. Allan DS, Buckstein R, Imrie KR. Outpatient supportive care following chemotherapy for acute myeloblastic leukemia. Leuk Lymphoma 2001;42(3):339-46.
9. Girmenia C, Alimena G, Latagliata R, et al. Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit. Haematologica 1999;84(9):814-9.
10. Uyl-de Groot CA, Okhuijsen SY, Hagenbeek A, et al. Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands. Bone Marrow Transplant 1995;15(4):605-10.
11. Pashko S, Jacobs J, Santorsa J. The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia. Clin Ther 1991;13(3):353-60.
12. Clavio M, Quintino S, Masoudi B, et al. Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens. J Exp Clin Cancer Res 2001;20(2):165-73.
13. Marie JP, Wdowik T, Bisserbe S, Zittoun R. Cost of complete remission induction in acute myeloblastic leukemia: evaluation of the cost-effectiveness of a new drug. Leukemia 1992;6(7):720-2.
14. Lobo PJ, Powles RL, Hanrahan A, Reynold DK. Acute myeloblastic leukaemia - a model for assessing value for money for new treatment programmes. BMJ 1991;302(6772):323-6.
15. Uyl-de Groot CA, Lowenberg B, Vellenga E, et al. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. Br J Haematol 1998;100(4):629-36.
16. Dufoir T, Saux MC, Terraza B, et al. Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. Bone Marrow Transplant 1992;10(4):323-9.
17. Barr R, Furlong W, Henwood J, et al. Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol 1996;14(5):1413-20.
18. Bone marrow transplantation and peripheral blood stem cell transplantation, National Cancer Institute. Available from: www.meb.uni-bonn.de/cancernet/400110.html, accessed July 2002.
19. Lee SJ, Klar N, Weeks JC, Antin JH. Predicting costs of stem-cell transplantation. J Clin Oncol 2000;18(1):64-71.
20. Wagner ND, Quinones VW. Allogeneic peripheral blood stem cell transplantation: clinical overview and nursing implications. Oncol Nurs Forum 1998;25(6):1049-55.
21. Bennett C, Waters T, Stinson T, et al. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;24(5):555-60.
22. Viens-Bitker C, Fery-Lemonnier E, Blum-Boisgard C, et al. Cost of allogeneic bone marrow transplantation in four diseases. Health Policy 1989;12(3):309-17.
23. Beard ME, Inder AB, Allen JR, et al. The costs and benefits of bone marrow transplantation. N Z Med J 1991;104(916): 303-5.
24. van Agthoven M, Groot MT, Verdonck LF, et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant 2002;30: 243-51.
25. Welch HG, Larson EB. Cost effectiveness of bone marrow transplantation in acute non-lymphocytic leukemia. N Engl J Med 1989;321(12):807-12.
26. Bennett CL, Hynes D, Godwin J, et al. Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a southwest oncology group clinical trial. Cancer Invest 2001;19(6):603-10.
27. Bennett CL, Stinson TJ, Tallman MS, et al. Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (>55-70 years of age) with acute myelogenous leukemia. Eastern cooperative oncology group (E1490). Ann Oncol 1999;10(2):177-82.
28. Lu ZJ, Luo R, Erder H, et al. Cost impact of Filgrastim as an adjunct to chemotherapy for patients with acute myeloid leukemia. Proc Am Soc Haematol 1996;88, Abstract 209a.
29. Bennett CL, Bishop MR, Tallman MS, Somerfield MR, Feinglass J, Smith TJ. The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American Society of Clinical Oncology survey. Health Services Research Committee of the American Society of Clinical Oncology. Ann Oncol 1999;10(11):1355-9.